The Microbiome-Bile Acid-Immune Axis in the Era of Emerging Therapies for Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) is a chronic immune-mediated cholestatic liver disease in which interactions among the intestinal microbiome, bile acid metabolism, and immune regulation may influence disease pathogenesis, progression, and therapeutic response. This narrative review synthesizes clinical and experimental evidence concerning the microbiome-bile acid-immune axis and its relevance to emerging therapeutic strategies. Studies involving patients with PBC have identified alterations in intestinal microbial composition and diversity, disturbances in bile acid profiles, and microbial signatures associated with biochemical response to ursodeoxycholic acid. Microbiome-derived metabolites, including short-chain fatty acids, secondary bile acids, and tryptophan derivatives, may influence intestinal barrier integrity, bile acid receptor signaling, and innate and adaptive immune responses. However, much of the mechanistic evidence originates from experimental models or other liver and immune-mediated diseases, and causal relationships in human PBC remain incompletely established. Emerging peroxisome proliferator-activated receptor agonists, particularly elafibranor and seladelpar, have demonstrated biochemical efficacy, while the potential contribution of microbiome-mediated mechanisms to their therapeutic effects remains uncertain. Microbiome-directed interventions, including probiotics and fecal microbiota transplantation, remain investigational in PBC. Longitudinal multi-omics investigations, functional studies, and prospective biomarker validation are essential to establish clinically relevant mechanisms and evaluate opportunities for more personalized therapeutic approaches.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-13
DOI
https://doi.org/10.20944/preprints202611.1420.v1
Primary Topic
Liver Diseases and Immunity
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

The Microbiome-Bile Acid-Immune Axis in the Era of Emerging Therapies for Primary Biliary Cholangitis

Emmanouil Magiorkinis, Ioanna Kotsiri, Eirini Papadakaki
1 links
Preprints.org
Liver Diseases and Immunity
preprint

The Microbiome-Bile Acid-Immune Axis in the Era of Emerging Therapies for Primary Biliary Cholangitis

Emmanouil Magiorkinis, Ioanna Kotsiri, Eirini Papadakaki
preprint en

Abstract

Primary biliary cholangitis (PBC) is a chronic immune-mediated cholestatic liver disease in which interactions among the intestinal microbiome, bile acid metabolism, and immune regulation may influence disease pathogenesis, progression, and therapeutic response. This narrative review synthesizes clinical and experimental evidence concerning the microbiome-bile acid-immune axis and its relevance to emerging therapeutic strategies. Studies involving patients with PBC have identified alterations in intestinal microbial composition and diversity, disturbances in bile acid profiles, and microbial signatures associated with biochemical response to ursodeoxycholic acid. Microbiome-derived metabolites, including short-chain fatty acids, secondary bile acids, and tryptophan derivatives, may influence intestinal barrier integrity, bile acid receptor signaling, and innate and adaptive immune responses. However, much of the mechanistic evidence originates from experimental models or other liver and immune-mediated diseases, and causal relationships in human PBC remain incompletely established. Emerging peroxisome proliferator-activated receptor agonists, particularly elafibranor and seladelpar, have demonstrated biochemical efficacy, while the potential contribution of microbiome-mediated mechanisms to their therapeutic effects remains uncertain. Microbiome-directed interventions, including probiotics and fecal microbiota transplantation, remain investigational in PBC. Longitudinal multi-omics investigations, functional studies, and prospective biomarker validation are essential to establish clinically relevant mechanisms and evaluate opportunities for more personalized therapeutic approaches.

Preprints.org
Good health and well-being
Liver Diseases and Immunity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon